METHODS OF PREDICTION, DETECTION AND REDUCTION OF NON-SPECIFIC INTERFERENCE OF PROTEINS IN METHODS OF ANALYSIS USING SINGLE VARIABLE DOMAINS OF IMMUNOGLOBULINS

摘要

1. A protein or polypeptide for use in therapy that has a half-life (expressed as t1 / 2-beta) in humans for at least 3 days, wherein the protein or polypeptide contains a single immunoglobulin variable domain (ISV) on its C- the end, wherein said ISV is either Nanobody or ISV that contains a VH sequence (i.e., different from Nanobody), or which is derived from a VH sequence, wherein the ISV has a VTVSS (X) sequence at the C-terminus, where: - n = 1, 2 or 3 (and preferably 1 or 2), in which each X = Ala or Gly; or n = 1, 2 or 3 (and preferably 1 or 2), in which each X = Ala; or n = 1, 2 or 3 (and preferably 1 or 2), in which each X = Gly; or n = 2 or 3, wherein at least one X = Ala or Gly (while the remaining amino acid residues X are independently selected from any natural amino acids, but preferably independently selected from Val, Leu and / or Ile); or n = 2 or 3, with all but one X = Ala or Gly (the remaining amino acid residues of X being independently selected from any naturally occurring amino acids, but preferably independently selected from Val, Leu and / or Ile) .2. The protein or polypeptide according to claim 1, in which: - n = 1, 2 or 3 (and preferably 1 or 2), in which each X = Ala or Gly; or n = 1, 2 or 3 (and preferably 1 or 2), in which each X = Ala; or n = 1, 2 or 3 (and preferably 1 or 2), in which each X = Gly3. The protein or polypeptide of claim 1, wherein X is not cysteine. A protein or polypeptide for use in therapy that has a half-life (expressed as t1 / 2-beta) in humans is at least 3 days, wherein the protein or polypeptide contains an ISV at its C-terminus, said ISV being either Nanobody or an ISV that contains a VH sequence